Company: VRCA
Filing Date: 2025-04-02
Form Type: 8-K
Source: 0001193125-25-071389
Chunk: 1

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-02
Form: 8-K
Item: Item 5.02
Chunk 1
---
an’s continuous service through such vesting dates. Additionally, Dr. Corcoran will be entitled to receive a $40,000 annual retainer for his service as director. At each annual stockholder meeting following which Dr. Corcoran’s term as a director continues, Dr. Corcoran will be entitled to receive an additional stock option to purchase 20,000 shares of the Company’s common stock, which option will vest and become exercisable in 12 equal monthly installments following the date of grant and in any event will be fully vested on the date of the next annual stockholder meeting, subject to Dr. Corcoran’s continuous service through such vesting date. Dr. Corcoran has also entered into the Company’s standard form of indemnification agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                           Verrica Pharmaceuticals Inc.     
  Date: April 2, 2025      /s/ John J. Kirby                
                           John J. Kirby                    
                           Interim Chief Financial Officer